Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Change in Accured Expenses (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Change in Accured Expenses data on record, last reported at $1.5 million in Q4 2022.

  • For Q4 2022, Change in Accured Expenses fell 85.98% year-over-year to $1.5 million; the TTM value through Dec 2022 reached -$37.6 million, down 185.75%, while the annual FY2025 figure was $12.7 million, 194.26% up from the prior year.
  • Change in Accured Expenses reached $1.5 million in Q4 2022 per AVIR's latest filing, down from $2.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $17.0 million in Q2 2021 and bottomed at -$28.0 million in Q1 2022.
  • Average Change in Accured Expenses over 3 years is $1.6 million, with a median of $2.8 million recorded in 2020.
  • Peak YoY movement for Change in Accured Expenses: surged 1886.52% in 2021, then crashed 522.66% in 2022.
  • A 3-year view of Change in Accured Expenses shows it stood at $8.2 million in 2020, then increased by 29.6% to $10.6 million in 2021, then crashed by 85.98% to $1.5 million in 2022.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.5 million in Q4 2022, $2.5 million in Q3 2022, and -$13.6 million in Q2 2022.